Mus­tang Bio to lay off work­ers; MaaT's new da­ta for mi­cro­bio­me ther­a­py

Mus­tang Bio ax­es 81% of staffers: The CAR-T cell ther­a­py com­pa­ny plans to im­ple­ment a work­force re­duc­tion through­out April to pre­serve cash in the sec­ond quar­ter. Mus­tang had 80 full-time em­ploy­ees as of the end of 2023, per an SEC fil­ing. — Ay­isha Shar­ma

MaaT Phar­ma de­tails da­ta for mi­cro­bio­me ther­a­py: The com­pa­ny’s lead can­di­date had 42% over­all sur­vival af­ter 18 months in a study with 140 pa­tients with acute graft ver­sus host dis­ease (aGvHD), demon­strat­ing a “high and durable re­sponse rate.” An­oth­er Phase 3 tri­al eval­u­at­ing the drug in cor­ti­cos­teroid and rux­oli­tinib-re­frac­to­ry aGvHD is on­go­ing. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER